Documenti di Didattica
Documenti di Professioni
Documenti di Cultura
or visit us online
Monday 01 May 2017
www.healthsave.com.au
Todays issue of PD
Pharmacy Daily today has
Hyland teething trouble Kiss MyAsthma app
Coinciding with World Asthma
After months of speculation substance, which may differ from Day, Asthma Australia has launched
two pages of news plus a full
around the quality and safety the calculated amounts listed on its Australian-developed mobile
page from Wizard Pharmacy.
of Hyland homeopathic infant the products labels. application named Kiss MyAsthma.
teething products, the Therapeutic At the time, the FDA urged the The new tool will support young
Contraception online Goods Administration has manufacturer to agree to a recall - a people to manage their asthma
not-for-profit reproductive announced that Kadac is recalling call which was rejected by Hyland and improve their quality of life,
health pharmaceutical company all batches of Hylands Baby (PD 30 Jan 17), resulting in the Asthma Australia said, adding that
Marie Stopes Health will be hosting teething tablets and Hylands Baby FDA re-issuing a formal warning to this is the first asthma app to use
a free educational webinar on nighttime teething tablets sold in stop using the Hylands products a co-design model, with young
the EllaOne (ulipristal acetate) Australia. and dispose of any tablets in their people actively involved in deciding
emergency contraceptive pill for Last year the US Food and Drug possession. the apps content and design.
pharmacists and other healthcare Administration (FDA) issued a In the meantime, the TGA had Asthma Australia funded a team
professionals on 10 May at 7pm. formal warning to consumers that conducted its own tests of the of researchers, clinicians and app
The webinar will cover general these teething products may pose Hylands products supplied in developers led by the University of
information about the product, its a health risk to infants and children Australia (PD 02 Feb 17), saying it Sydney to create the app to address
efficacy and safety, how to advise (PD 04 Oct 16). found no quality issues. the needs of young people, who
women, their knowledge and The FDA had conducted an Despite this Kadac is now recalling also gave the app its decidedly
preferences, as well as frequently investigation and determined that the tablets as a precautionary memorable name.
asked questions. these products supplied in the US measure due to the potential Kiss MyAsthma users receive
There will also be an interactive contained inconsistent amounts safety risks that belladonna notifications from a cast of monster
Q&A session. of belladonna alkaloids, a toxic alkaloids can pose to children. characters who provide friendly
Pharmacists can register to Belladonna effects can be reminders and opportunities to
participate at goo.gl/E1OAa9. unpredictable and could cause adjust goals to keep them on track.
Plain cig packs work serious health problems, including Interface and UX Specialist at
Standardised cigarette seizures in children, the TGA said. the University of Sydney Dorian
packaging may reduce the number Hylands Baby teething tablets or Peters said, By working with users
of people who smoke, a Cochrane Hylands Baby nighttime teething from the beginning we discovered
review has concluded, with the tablets can be returned to the point that psychological impacts are
project mimicking Australias of purchase for a full refund or call an important part of the asthma
approach since 2012 being adopted Kadac on 1300 762 025, the TGA experience, so the design takes this
in the UK this month. has said, advising consumers to into account - from the features we
speak to their pharmacist for more included right down to the friendly
Prescribing The rules require packs to be
produced in a drab dark brown, advice on ways to manage infant characters, calming colours and
Confidence with with only minimal text including teething issues. imagery we used.
BioCeuticals the manufacturers brand name in
IT MAKES SENSE
size 14 font.
& IMgateway France implemented the policy
o1 Jan this year and several other
IF YOU DISPENSE
Quickly and easily access
drug and herb interaction countries are planning to follow.
information via your Visit bmj.com for the abstract.
BioCeuticals website
login for free
Easy to understand
traffic-light system to
New MS option PBS
instantly view warnings Biogen has announced that
and cautions Zinbryta (daclizumab) is available
Comprehensive, on the Pharmaceutical Benefits
independently verified Scheme (PBS) from today for the
herb and nutrient drug
interaction information treatment of relapsing-remitting
at your fingertips multiple sclerosis
It is currently listed on the ARTG
for the treatment of relapsing
forms of MS, to delay the
progression of physical disability
Click for more information and to reduce the frequency of
or call 1300 650 455 relapse.
www.bioceuticals.com.au Zinbryta is a once-monthly self-
administered injection which works
by stopping the bodys immune
system from damaging the brain
and spinal cord, Biogen has said.
Subscribe for free
Pharmacy Daily Monday 1st May 2017 t 1300 799 220 w www.pharmacydaily.com.au page 1
Follow us
on social media
Just one click away from keeping up
to date with all the Pharmacy Daily
Monday 01 May 2017 breaking news as it comes to hand
Pharmacy Daily is Australias favourite pharmacy industry publication. Publisher/Editor in chief: Bruce Piper Editorial: info@pharmacydaily.com.au
Sign up free at www.pharmacydaily.com.au. Managing Editor: Jon Murrie
Postal address: PO Box 1010, Epping, NSW 1710 Australia Reporter: Mal Smith
Street address: Level 2, Suite 1 64 Talavera Rd, Macquarie Park NSW 2113 Australia Contributors: Matt Bell, Rebecca Le Bas, Jasmine ODonoghue
Advertising and Marketing: Sean Harrigan and Melanie Tchakmadjian advertising@pharmacydaily.com.au
P: 1300 799 220 (+61 2 8007 6760) F: 1300 799 221 (+61 2 8007 6769)
Business Manager: Jenny Piper accounts@pharmacydaily.com.au
Part of the Business Publishing Group.
business events news
Pharmacy Daily is a publication of Pharmacy Daily Pty Ltd ABN 97 124 094 604. All content fully protected by copyright. Please obtain written permission to reproduce any material. While every care has been taken in the preparation of
the newsletter no liability can be accepted for errors or omissions. Information is published in good faith to stimulate independent investigation of the matters canvassed. Responsibility for editorial comment is taken by Bruce Piper.
Pharmacy Daily Monday 1st May 2017 t 1300 799 220 w www.pharmacydaily.com.au page 2
SCRIPT
SO YOU DONT
THE LINES.
SIGNED